$3.55 Billion is the total value of BB BIOTECH AG's 30 reported holdings in Q4 2015. The portfolio turnover from Q3 2015 to Q4 2015 was 14.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CELG | Buy | Celgene Corp. | $432,250,000 | +11.3% | 3,609,298 | +0.6% | 12.18% | -1.1% |
| INCY | Incyte Corp. | $406,732,000 | -1.7% | 3,750,406 | 0.0% | 11.46% | -12.7% | |
| IONS | New | Ionis Pharmaceuticals Inc. | $404,393,000 | – | 6,529,838 | +100.0% | 11.39% | – |
| GILD | Gilead Sciences Inc. | $280,761,000 | +3.1% | 2,774,596 | 0.0% | 7.91% | -8.4% | |
| RDUS | Radius Health Inc. | $262,907,000 | -11.2% | 4,272,140 | 0.0% | 7.41% | -21.1% | |
| ALXN | Alexion Pharmaceuticals Inc. | $197,317,000 | +22.0% | 1,034,428 | 0.0% | 5.56% | +8.3% | |
| NBIX | Sell | Neurocrine Biosciences Inc. | $176,586,000 | +39.9% | 3,121,552 | -1.6% | 4.97% | +24.3% |
| VRTX | Vertex Pharmaceuticals Inc. | $171,814,000 | +20.8% | 1,365,445 | 0.0% | 4.84% | +7.3% | |
| AGIO | Buy | Agios Pharmaceuticals Inc. | $140,222,000 | -5.9% | 2,159,921 | +2.4% | 3.95% | -16.4% |
| MDVN | Medivation Inc. | $124,771,000 | +13.7% | 2,581,112 | 0.0% | 3.52% | +1.1% | |
| HALO | Buy | Halozyme Therapeutics Inc. | $121,827,000 | +30.9% | 7,029,832 | +1.4% | 3.43% | +16.3% |
| REGN | Regeneron Pharmaceuticals Inc. | $111,288,000 | +16.7% | 205,000 | 0.0% | 3.14% | +3.7% | |
| ALNY | Alnylam Pharmaceuticals Inc. | $106,613,000 | +17.1% | 1,132,499 | 0.0% | 3.00% | +4.1% | |
| NVAX | Novavax Inc. | $69,889,000 | +18.7% | 8,330,000 | 0.0% | 1.97% | +5.5% | |
| TSRO | Buy | Tesaro Inc. | $64,332,000 | +38.9% | 1,229,582 | +6.5% | 1.81% | +23.4% |
| CEMP | Buy | Cempra Inc. | $62,008,000 | +17.7% | 1,991,900 | +5.3% | 1.75% | +4.6% |
| JUNO | Juno Therapeutics, Inc. | $57,381,000 | +8.1% | 1,305,000 | 0.0% | 1.62% | -4.0% | |
| ALDR | Alder Biopharmaceuticals Inc. | $49,880,000 | +0.8% | 1,510,150 | 0.0% | 1.40% | -10.5% | |
| KITE | Kite Pharma, Inc. | $46,215,000 | +10.7% | 750,000 | 0.0% | 1.30% | -1.7% | |
| PTCT | PTC Therapeutics Inc. | $42,214,000 | +21.3% | 1,302,912 | 0.0% | 1.19% | +7.8% | |
| SAGE | New | Sage Therapeutics, Inc. | $41,315,000 | – | 708,663 | +100.0% | 1.16% | – |
| ICPT | Buy | Intercept Pharmaceuticals Inc. | $38,192,000 | +9.3% | 255,719 | +21.4% | 1.08% | -2.9% |
| PBYI | Sell | Puma Biotechnology Inc. | $33,868,000 | -13.9% | 431,991 | -17.2% | 0.95% | -23.5% |
| PRTA | Prothena Corp. PLC | $21,795,000 | +50.2% | 320,000 | 0.0% | 0.61% | +33.5% | |
| INFI | Infinity Pharmaceuticals Inc. | $21,201,000 | -7.1% | 2,700,737 | 0.0% | 0.60% | -17.5% | |
| ESPR | Esperion Therapeutics, Inc. | $20,224,000 | -5.6% | 908,542 | 0.0% | 0.57% | -16.2% | |
| CLVS | Sell | Clovis Oncology Inc. | $18,487,000 | -67.5% | 528,188 | -14.6% | 0.52% | -71.1% |
| ACHN | Achillion Pharmaceuticals Inc. | $13,804,000 | +56.2% | 1,279,340 | 0.0% | 0.39% | +38.9% | |
| CDTX | New | Cidara Therapeutics, Inc. | $8,008,000 | – | 466,679 | +100.0% | 0.23% | – |
| TTPH | Sell | Tetraphase Pharmaceuticals Inc. | $3,673,000 | -66.8% | 366,203 | -75.3% | 0.10% | -70.7% |
| ISIS | Exit | Isis Pharmaceuticals Inc. | $0 | – | -6,634,838 | -100.0% | -8.50% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Biotech Focus N.V. #1
- Biotech Invest N.V. #2
- Biotech Target N.V. #3
- Biotech Growth N.V. #4
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-02-09
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Celgene Corporation | 24 | Q1 2019 | 18.3% |
| Incyte Corporation | 24 | Q1 2019 | 15.3% |
| Gilead Sciences, Inc. | 24 | Q1 2019 | 14.2% |
| Vertex Pharmaceuticals Incorporated | 24 | Q1 2019 | 8.1% |
| Alexion Pharmaceuticals, Inc. | 24 | Q1 2019 | 5.7% |
| Halozyme Therapeutics, Inc. | 24 | Q1 2019 | 4.9% |
| Alnylam Pharmaceuticals, Inc. | 24 | Q1 2019 | 3.8% |
| Neurocrine Biosciences, Inc. | 23 | Q1 2019 | 10.3% |
| Regeneron Pharmaceuticals, Inc. | 22 | Q4 2018 | 3.5% |
| Achillion Pharmaceuticals, Inc. | 22 | Q3 2018 | 1.0% |
View BB BIOTECH AG's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Kezar Life Sciences, Inc. | February 14, 2023 | 3,000,000 | 4.4% |
| Mersana Therapeutics, Inc. | February 14, 2023 | 4,066,200 | 4.1% |
| Molecular Templates, Inc. | February 14, 2023 | 11 | 19.9% |
| Myovant Sciences Ltd. | February 14, 2023 | 5,872,639 | 6.0% |
| Scholar Rock Holding Corp | February 14, 2023 | 2,132,725 | 4.1% |
| Radius Health, Inc.Sold out | August 30, 2022 | 0 | 0.0% |
| Cidara Therapeutics, Inc.Sold out | February 11, 2022 | 0 | 0.0% |
| Voyager Therapeutics, Inc.Sold out | February 11, 2022 | 0 | 0.0% |
| HALOZYME THERAPEUTICS, INC. | February 12, 2021 | 3,970,000 | 2.9% |
| Intra-Cellular Therapies, Inc. | February 12, 2021 | 3,538,419 | 4.4% |
View BB BIOTECH AG's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-22 |
| 4 | 2024-04-04 |
| 13F-NT | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
View BB BIOTECH AG's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.